Coverage
-
January 11, 2013
A Tennessee federal judge on Thursday tossed a shareholder class action against BioMimetic Therapeutics Inc. and its two top executives, ruling that the plaintiffs had failed to prove the orthopedics company lied about the progress of approval for a bone injury treatment that decimated its stock price.
1 other articles on this case.
View all »